Document:

Exhibit 10.4

 

EXECUTIVE
RETENTION AGREEMENT

 

This
Executive Retention Agreement (the “Agreement”) is made and entered into as of October 25, 2017 by and
between GENEXOSOME TECHNOLOGIES INC., a Delaware corporation (the “Company”), and YU ZHOU (the “Executive”).

 

Recitals:

 

WHEREAS,
the Executive is a key employee of the Company who possesses valuable proprietary knowledge of the Company, its business and operations
and the markets in which the Company competes; and

 

WHEREAS,
the Company and the Executive desire to enter into this Agreement to encourage the Executive to continue to devote the Executive’s
full attention and dedication to the success of the Company, and to provide specified compensation and benefits to the Executive
in the event of certain terminations pursuant to the terms of this Agreement.

 

NOW,
THEREFORE, THE PARTIES HEREBY AGREE AS FOLLOWS:

 

1.            PURPOSE
AND TERM; DUTIES

 

1.1          The
purpose of this Agreement is to provide specified compensation and benefits to the Executive in the event of an Involuntary Termination.
Subject to the terms of any applicable written employment agreement between Company and the Executive (as to which Executive acknowledges
no other such agreement exists as of the date hereof), either the Executive or Company may terminate the Executive’s employment
at any time for any reason, with or without notice. The term of this Agreement shall be the period from the date set forth above
until Executive’s employment is terminated for any reason or this Agreement is terminated by mutual agreement of the parties.

 

1.2          The
Executive’s job responsibilities as Co-Chief Executive Officer will comprise of:

 

(a)          developing
high quality business strategies and plans ensuring their alignment with short-term and long-term objectives,

 

(b)          managing,
leading and motivating subordinates to advance employee engagement 

 

(c)          developing
a high performing managerial team and overseeing all operations and business activities to ensure they produce the desired results
and are consistent with the overall strategy and mission of the Company as established by the Board of Directors. 

 

1.3          The
Executive will from the Company’s corporate offices but agrees that significant travel will be required including international
travel. The Executive is entitled to four (4) weeks of vacation which will accrue on a pro-rata basis
during the year, in addition to all public holidays when the office is closed.   Executive will be eligible to participate
in all employee benefit plans established by the Company for its employees from time to time. In accordance with Company policies
from time to time, Executive will reimburse you for all reasonable and proper travel and business expenses incurred by you in
the performance of your duties that are approved in writing by the Chief Financial Officer.

 

    	-1- 

     

    

 

2.            COMPENSATION
AND TERMINATION GENERALLY

 

2.1          Compensation.

 

2.1.1          Annual
Salary. The Executive’s base salary shall be $160,000 per annum and shall be subject to periodic review and modification
by the Company’s Board of Directors (the “Board”) as may be delegated to the Compensation Committee
of the Board (references herein to the Compensation Committee shall include reference to the Board if no such Committee exists
at any time) at such time or times as it shall determine. The Company’s Compensation Committee shall also from time to time,
in its discretion, determine the type and amount of other forms of compensation for Executive’s service with the Company
(including, without limitation, stock options or other forms of equity awards).

 

2.1.2          Bonuses.
Executive shall be entitled to bonuses as determined by the Board of Directors.

 

2.2          Termination
of Employment Generally. In the event the Executive’s employment with the Company terminates, for any reason whatsoever
including death or disability the Executive shall be entitled to the benefits described in this Section 2.2.

 

2.2.1          Accrued
Salary and Vacation. All salary and accrued vacation earned through the Termination Date shall be paid to Executive on such
date.

 

2.2.2          Accrued
Bonus Payment. The Executive shall receive a lump sum payment of any actual bonus amount to the extent that all the conditions
for payment of such bonus have been satisfied and any such bonus was earned and is unpaid on the Termination Date.

 

2.2.3          Expense
Reimbursement. Within ten (10) days following submission to the Company of proper expense reports by the Executive, the Company
shall reimburse the Executive for all expenses incurred by the Executive, consistent with the Company’s expense reimbursement
policy in effect prior to the incurring of each such expense, in connection with the business of the Company prior to the Termination
Date.

 

3.            INVOLUNTARY
TERMINATION

 

3.1          Salary
Payment. In the event of the Executive’s Involuntary Termination, during the period commencing on the date hereof and
continuing for a period of two years, the Executive shall continue to receive Executive’s base salary at normal pay intervals
through October 20, 2019.

 

4.            DEFINITIONS

 

4.1          Capitalized
Terms Defined. Capitalized terms used in this Agreement shall have the meanings set forth in this Section 4, unless the context
clearly requires a different meaning.

 

4.2          “Base
Salary” means the monthly salary of the Executive in effect immediately prior to the Termination Date.

 

    	-2- 

     

    

 

4.3          “Cause”
means:

 

		(a)	the
                                         Executive willfully failed to follow the lawful written directions of the Board of Directors
                                         of the Company or Executive’s immediate superior; provided that no termination
                                         for such Cause shall occur unless the Executive: (i) has been provided with notice, specifying
                                         such willful failure in reasonable detail, of the Company’s intention to terminate
                                         the Executive for Cause; and (ii) has failed to cure or correct such willful failure
                                         within ten (10) days of receiving such notice; 

 

		(b)	the
                                         Executive engaged in gross misconduct, or gross incompetence which is materially detrimental
                                         to the Company; provided that no termination for such Cause shall occur unless the Executive:
                                         (i) has been provided with notice, specifying such gross misconduct or gross incompetence
                                         in reasonable detail, of the Company’s intention to terminate the Executive for
                                         Cause; and (ii) has failed to cure or correct such gross misconduct within ten (10) days
                                         of receiving such notice; 

 

		(c)	the
                                         Executive willfully failed to comply in any material respect with the Employee Invention
                                         Assignment, Confidentiality, Non-Compete and Non-Solicit Agreement (the “Invention
                                         Agreement”) or any other reasonable policies of the Company where non-compliance
                                         would be materially detrimental to the Company; provided that no termination for such
                                         Cause shall occur unless the Executive: (i) has been provided with notice of the Company’s
                                         intention to terminate the Executive for such Cause, and (ii) has failed to cure or correct
                                         such willful failure within ten (10) days of receiving such notice, provided that such
                                         notice and cure period requirements shall not apply in the event that such non-compliance
                                         is of a nature that it is unable to be remedied; or

 

		(d)	is
                                         indicted, charged or convicted of a felony or crime involving moral turpitude (excluding
                                         drunk driving unless combined with other aggravating circumstances or offenses) or commission
                                         of a fraud which the Company reasonably believes would reflect adversely on the Company.

 

4.4          
“Company” shall mean Genexosome Technologies Inc..

 

4.5          “Involuntary
Termination” means:

 

		(a)	any
                                         termination without Cause of the employment of the Executive by the Company; or

 

		(b)	any
                                         resignation by Executive for Good Reason where such resignation occurs within ten (10)
                                         days following the occurrence of such Good Reason.

 

Notwithstanding
the foregoing, the term “Involuntary Termination” shall not include any termination of the employment of the Executive:
(1) by the Company for Cause; (2) by the Company as a result of the Permanent Disability of the Executive; (3) as a result
of the death of the Executive; or (5) as a result of the voluntary termination of employment by the Executive for any reason other
than Good Reason.

 

    	-3- 

     

    

 

4.6          
“Good Reason” means the occurrence of any of the following conditions, without the Executive’s written
consent:

 

		(a)	A
                                         reduction in the Executive’s Base Salary. 

 

		(b)	The
                                         failure of the Company (i) to continue to provide the Executive an opportunity to participate
                                         in any benefit or compensation plans provided to employees who hold positions with the
                                         Company comparable to the Executive’s position, or (ii) to provide the Executive
                                         all other fringe benefits (or the equivalent) in effect for the benefit of any employee
                                         group which includes any employee who hold a position with the Company comparable to
                                         the Executive’s position.

 

		(c)	A
                                         material breach of this Agreement by the Company.

 

The
Executive must first give the Company an opportunity to cure any of the foregoing within thirty (30) days following delivery to
the Company of a written explanation specifying the specific basis for Executive’s belief that Executive is entitled to
terminate employment for Good Reason, and Executive terminates employment with the Company not later than (30) days following
the Company’s failure to cure.

 

4.7          
“Permanent Disability” means that:

 

		(a)	the
                                         Executive has been incapacitated by bodily injury, illness or disease so as to be prevented
                                         thereby from engaging in the performance of the Executive’s duties;

 

		(b)	such
                                         total incapacity shall have continued for a period of six consecutive months; and

 

		(c)	such
                                         incapacity will, in the opinion of a qualified physician, be permanent and continuous
                                         during the remainder of the Executive’s life.

 

4.8          
“Termination Date” means the date of the termination of the Executive’s employment with the Company.

 

5.            EXCLUSIVE
REMEDY

 

5.1          No
Other Benefits Payable. The Executive shall be entitled to no other termination, severance or compensation, benefits, or other
payments from the Company as a result of any termination with respect to which the payments and benefits described in Section
2 have been provided to the Executive, except as expressly set forth in this Agreement.

 

5.2          No
Limitation of Regular Benefit Plans. Except as may be provided elsewhere in this Agreement, this Agreement is not intended
to and shall not affect, limit or terminate any plans, programs or arrangements of the Company that are regularly made available
to a significant number of employees or officers of the Company, including, without limitation, the Company’s stock option
plans.

 

    	-4- 

     

    

 

5.3          Release
of Claims. The payment of the benefits described in Sections 3 and 4 of this Agreement is conditioned upon the delivery by
the Executive to the Company of a signed and effective general release of claims as provided by the Company; provided, however,
that the Executive shall not be required to release any rights the Executive may have to be indemnified by the Company or as otherwise
provided under this Agreement.

 

6.            NON-COMPETE;
PROPRIETARY AND CONFIDENTIAL INFORMATION

 

During
the term of this Agreement and following any termination of employment, Executive agrees to continue to abide by the terms and
conditions of the Invention Agreement.

 

7.            ARBITRATION

 

7.1          Disputes
Subject to Arbitration. Any claim, dispute or controversy arising out of this Agreement (other than claims relating to misuse
or misappropriation of the intellectual property of the Company), the interpretation, validity or enforceability of this Agreement
or the alleged breach thereof shall be submitted by the parties to binding arbitration by a sole arbitrator under the rules of
the American Arbitration Association; provided, however, that (a) the arbitrator shall have no authority to make any ruling or
judgment that would confer any rights with respect to the trade secrets, confidential and proprietary information or other intellectual
property of the Company upon the Executive or any third party; and (b) this arbitration provision shall not preclude the Company
from seeking legal and equitable relief from any court having jurisdiction with respect to any disputes or claims relating to
or arising out of the misuse or misappropriation of the Company’s intellectual property. Judgment may be entered on the
award of the arbitrator in any court having jurisdiction.

 

7.2          Costs
of Arbitration. All costs of arbitration, including reasonable attorney’s fees of the Executive, will be borne by the
Company, except that if the Executive initiates arbitration and the arbitrator finds the Executive’s claims to be frivolous
the Executive shall be responsible for his own costs and attorneys fees.

 

7.3          Site
of Arbitration. The site of the arbitration proceeding shall be in Monmouth County, New Jersey.

 

8.            NOTICES

 

For
purposes of this Agreement, notices and all other communications provided for in the Agreement shall be in writing and shall be
deemed to have been duly given when delivered or five (5) business days after being mailed, return receipt requested, as follows:
(a) if to the Company, attention: Chief Executive Officer, at the Company’s offices at 83 South Street, Suite 101, Freehold,
New Jersey 07728 and, (b) if to the Executive, at the address indicated below or such other address specified by the Executive
in writing to the Company. Either party may provide the other with notices of change of address, which shall be effective upon
receipt.

 

9.            MISCELLANEOUS
PROVISIONS

 

9.1          Heirs
and Representatives of the Executive; Successors and Assigns of the Company. This Agreement shall be binding upon and shall
inure to the benefit of and be enforceable by the Executive’s personal and legal representatives, executors, administrators,
successors, heirs, distributees, devises and legatees. This Agreement shall be binding upon and inure to the benefit of and be
enforceable by the successors and assigns of the Company.

 

    	-5- 

     

    

 

9.2          Amendment
and Waiver. No provision of this Agreement shall be modified, amended, waived or discharged unless the modification, amendment,
waiver or discharge is agreed to in writing, specifying such modification, amendment, waiver or discharge, and signed by the Executive
and by an authorized officer of the Company (other than the Executive). No waiver by either party of any breach of, or of compliance
with, any condition or provision of this Agreement by the other party shall be considered a waiver of any other condition or provision
or of the same condition or provision at another time.

 

9.3          Withholding
Taxes. All payments made under this Agreement shall be subject to deduction of all federal, state, local and other taxes required
to be withheld by applicable law.

 

9.4          Severability.
The invalidity or unenforceability of any provision or provisions of this Agreement shall not affect the validity or enforceability
of any other provision hereof, which shall remain in full force and effect.

 

9.5          Choice
of Law. The validity, interpretation, construction and performance of this Agreement shall be governed by the laws of the
State of New Jersey, without regard to where the Executive has his residence or principal office or where he performs his duties
hereunder.

 

9.6          No
Duty to Mitigate. The Executive is not required to seek alternative employment following termination, and payments called
for under this Agreement will not be reduced by earnings from any other source.

 

9.7.          Section
409A of the Code. To the extent (a) any payments or benefits to which Employee becomes entitled under this Agreement, or under
any agreement or plan referenced herein, in connection with Employee’s termination of employment with the Company constitute
deferred compensation subject to Section 409A of the Code and (b) Employee is deemed at the time of such termination of employment
to be a “specified employee” under Section 409A of the Code, then such payments shall not be made or commence until
the earliest of (i) the expiration of the six (6)-month period measured from the date of Employee’s “separation from
service” (as such term is at the time defined in Treasury Regulations under Section 409A of the Code) from the Company;
or (ii) the date of Employee’s death following such separation from service; provided, however, that such deferral shall
only be effected to the extent required to avoid adverse tax treatment to Employee, including (without limitation) the additional
twenty percent (20%) tax for which Employee would otherwise be liable under Section 409A(a)(1)(B) of the Code in the absence of
such deferral. Upon the expiration of the applicable deferral period, any payments which would have otherwise been made during
that period (whether in a single sum or in installments) in the absence of this paragraph shall be paid to Employee or Employee’s
beneficiary in one lump sum (without interest). Any termination of Employee’s employment is intended to constitute a “separation
from service” as such term is defined in Treasury Regulation Section 1.409A-1. It is intended that each installment of the
payments provided hereunder constitute separate “payments” for purposes of Treasury Regulation Section 1.409A-2(b)(2)(i).
It is further intended that payments hereunder satisfy, to the greatest extent possible, the exemption from the application of
Code Section 409A (and any state law of similar effect) provided under Treasury Regulation Section 1.409A-1(b)(4) (as a “short-term
deferral”).

 

9.8          Entire
Agreement. This Agreement represents the entire agreement and understanding between the parties as to the subject matter herein
(whether oral or written and whether express or implied).

 

[SIGNATURE
PAGE TO EXECUTIVE RETENTION AGREEMENT FOLLOWS]

 

    	-6- 

     

    

 

In
Witness Whereof, each of the parties has executed
this Agreement, in the case of the Company, by its duly authorized officer, as of the day and year first above written.

 

	 	Executive
	 	 
	 	/s/ Yu Zhou
	 	Yu Zhou
	 	 
	 	GenExosome Technologies Inc.
	 	 
	 	By:	/s/ David Jin
	 	 	David
Jin, Co-CEOExhibit 10.5

 

EMPLOYEE
INVENTION ASSIGNMENT, CONFIDENTIALITY, NON-COMPETE  

AND
NON-SOLICIT AGREEMENT

 

THIS
EMPLOYEE INVENTION ASSIGNMENT, CONFIDENTIALITY, NON-COMPETE AND NON-SOLICIT AGREEMENT is entered into as of the 25th day of
October, 2017 between the undersigned Yu Zhou and GENEXOSOME TECHNOLOGIES INC., a Nevada corporation with a place
of business at 83 South Street, Suite 101, Freehold, New Jersey 07728 USA, (the “Company”).

 

WHEREAS,
I have agreed to be an employee of the Company or one of its affiliated entities (collectively referred to herein as the “Company”).

 

IN
CONSIDERATION OF, and as a condition of my employment with the Company (the receipt and sufficiency of which I hereby acknowledge)
I hereby represent to, and agree with the Company as follows:

 

1.          
Purpose of Agreement. I understand that it is critical for the Company to preserve and protect its rights in “Inventions”
(as defined in Section 2 below), its “Confidential Information” (as defined in Section 7
below) and in all related intellectual property rights. Accordingly, I am entering into this Employee Invention Assignment and
Confidentiality Agreement (this “Agreement”) as a condition of my employment with the Company.

 

2.          
Disclosure of Inventions. I will promptly disclose in confidence to the Company all inventions, improvements, designs,
original works of authorship, formulas, processes, compositions of matter, computer software programs, databases, mask works and
trade secrets (the “Inventions”) that I make or conceive or first reduce to practice or create, either
alone or jointly with others, during the period of my employment, whether or not in the course of my employment, and whether or
not such Inventions are patentable, copyrightable or protectable as trade secrets.

 

3.          
Work for Hire. I acknowledge and agree that any copyrightable works prepared by me within the scope of my employment,
including for the avoidance of doubt any such works prepared prior to the date hereof are “works made for hire” under
the Copyright Law of the United States and that the Company will be considered the author and owner of such copyrightable works.

 

4.          
Assignment of Inventions. I agree that all Inventions that (i) have been or are developed using equipment, supplies,
facilities, Confidential Information, or trade secrets of the Company, (ii) result from work performed by me for the Company,
or (iii) relate to the Company’s business or current or anticipated research and development (the “Assigned
Inventions”), will be the sole and exclusive property of the Company and are hereby irrevocably assigned by me to
the Company. 

 

5.          
Assignment of Other Rights; Moral Rights. In addition to the foregoing assignment of Assigned Inventions to the Company,
I hereby irrevocably transfer and assign to the Company: (i) all worldwide patents, patent applications, copyrights, mask
works, trade secrets and other intellectual property rights, including but not limited to rights in databases, in any Assigned
Inventions, along with any registrations of or applications to register such rights; and (ii) any and all “Moral Rights”
(as defined below) that I may have in or with respect to any Assigned Inventions. I also hereby forever waive and agree never
to assert any and all Moral Rights I may have in or with respect to any Assigned Inventions, even after termination of my work
on behalf of the Company. “Moral Rights” mean any rights to claim authorship of or credit on an Assigned
Invention, to object to or prevent the modification or destruction of any Assigned Inventions, or to withdraw from circulation
or control the publication or distribution of any Assigned Inventions, and any similar right, existing under judicial or statutory
law of any country or subdivision thereof in the world, or under any treaty, regardless of whether or not such right is denominated
or generally referred to as a “moral right.” 

 

    	1 

     

    

 

 

6.          
Assistance. I agree to assist the Company in every proper way, at the Company’s cost, to obtain for the Company
and enforce patents, copyrights, mask work rights, trade secret rights and other legal protections for the Company’s Assigned
Inventions in any and all countries. I will execute any documents that the Company may reasonably request for use in obtaining
or enforcing such patents, copyrights, mask work rights, trade secrets and other legal protections. My obligations under this
paragraph will continue beyond the termination of my employment with the Company, provided that the Company will compensate me
at a reasonable rate after such termination for time or expenses actually spent by me at the Company’s request on such assistance.
I appoint the Secretary of the Company as my attorney-in-fact to execute documents on my behalf for this purpose.

 

7.          
Confidential Information. I understand that my employment by the Company creates a relationship of confidence and trust
with respect to any information that may be disclosed to me by the Company and its officers, employees, shareholders or agents,
whether orally, in writing, by computer or other medium, by demonstration, by supply of samples and parts or in any other manner,
or which is otherwise accessible to me, that relates to the business of the Company or to the business of any parent, subsidiary,
affiliate, customer or supplier of the Company including all information received by the Company from third parties, which is
subject to an obligation of confidentiality (the “Confidential Information”). Such Confidential Information
includes, but is not limited to, Assigned Inventions, computer programming and software, Company products and services, systems,
functionality, designs, hardware, parts, concepts, specifications, features, techniques, plans, marketing, sales, performance,
cost, pricing, supplier and customer information, data, tables, schedules, contracts and other information concerning the Company
and its customers. I hereby acknowledge that all such Confidential Information belongs to the Company (or the respective customer,
supplier or third party, which supplied it to the Company.)

 

8.          
Confidentiality. At all times, both during my employment and after its termination (without limitation in point of
time), I will keep and hold all such Confidential Information in strict confidence and trust. I will not use or disclose any Confidential
Information without the prior written consent of the Company, except as may be necessary to perform my duties as an employee of
the Company for the benefit of the Company. Upon termination of my employment with the Company, I will promptly deliver to the
Company all documents and materials of any nature pertaining to my work with the Company. I will not take with me or retain any
documents or materials or copies thereof containing any Confidential Information. I agree that I shall at all times comply with
the Company’s Information Security Policy and Procedures from time to time in force. I acknowledge that breach of this
policy or any other provision of this Agreement may be grounds for immediate dismissal.

 

9.          
No Breach of Agreement or Infringement. I represent that my acceptance of the Company’s offer of employment,
performance of all the terms of this Agreement and my duties as an employee of the Company will not so far as I am aware breach
any invention assignment, proprietary information, confidentiality or similar agreement with any other party, nor infringe the
rights of any third party. I represent that I will not bring with me to the Company or use in the performance of my duties for
the Company any documents or materials or intangibles of a former employer or third party that are not generally available to
the public or have not been legally transferred to the Company. I acknowledge that the Company is relying upon my warranty, representation
and acknowledgement in this paragraph in offering me employment. 

 

10.       
Non-Complete. I acknowledge that the Company and its affiliates have invested substantial time, money and resources
in the development and retention of their respective customers, accounts and Confidential Information. You acknowledge and agree
that any and all “goodwill” associated with any customer or account of the Company or any of its affiliates belongs
exclusively to the Company and/or its affiliates, as the case may be. I further acknowledge and agree that, during the course
of performing services the Company will, and its affiliates may, furnish, disclose or make available to you confidential and proprietary
information related to the Company’s and its affiliates’ business(es) and that the Company and/or one or more affiliates may provide
you with unique and specialized training. I also acknowledge that such confidential information and such training have been developed
and will be developed by the Company and/or one or more affiliates through the expenditure by the Company and/or one or more affiliates
of substantial time, effort and money and that all such confidential information and training could be used by you to compete
with the Company and/or one or more affiliates. In recognition of this, you covenant and agree as follows:

 

    	2 

     

    

 

(a)       I
understand and acknowledge that the Company’s and its affiliates’ business interests are world-wide because the Company’s and
its affiliates’ products and/or services are sold in countries around the world and the Company’s and its affiliates’ competitors
similarly operate from and market their products and/or services in many locations around the world. As used in this Agreement
(i) the term “Company Business” means any component or facet of business pertaining to the exosome field
engaged in by the Company or any of its affiliates at any time anywhere in the world during your engagement by the Company and
(ii) the term “Competitive Business” means any Company Business engaged in by any third party anywhere in
the world.

 

(b)       From
the date hereof until the date that is the second anniversary date of the termination of your employment with the Company (or
any Affiliate, as applicable and whichever is later) (the “Restricted Period”), I shall not, directly or indirectly,
without the prior written consent of the Company, individually or in partnership with, as part of a joint venture with, or otherwise
in conjunction in any other manner with any other entity:

 

(i)       be
engaged in any manner whatsoever, including, without limitation, as an employee, employer, owner, partner, consultant, adviser,
principal, agent, stockholder, member or proprietor, in any Competitive Business;

 

(ii)
      either individually or on behalf of or through any third party, solicit, divert or appropriate
or attempt to solicit, divert or appropriate, for the purpose of competing with any Company Business, any customers or patrons
of any Company Business, or any prospective customers or patrons with respect to which the Company or any Affiliate has developed
or made a sales presentation (or similar offering of services); or

 

(iii)      advise, invest in, lend money to, guarantee the debts or obligations of, or otherwise have any other financial
interest in any Competitive Business. Notwithstanding the foregoing, I shall be permitted to make wholly passive investments
in any publicly held Competitive Business, provided that my direct and indirect ownership shall not exceed 1 % (by
voting power) of the aggregate ownership interests in the entity conducting such Competitive Business.

 

11.         No Solicitation. 

 

(a)       No
Solicitation of Employees. I acknowledge the importance to the business carried on by the Company and its affiliates
of the human resources engaged and developed by such entities. Accordingly, during the Restricted Period, I covenant and agree
that I shall not, directly or indirectly, induce or solicit or assist any third party in inducing or soliciting any employee or
consultant of the Company or any affiliate to leave the Company or any affiliate or to accept employment or engagement elsewhere.
The Company acknowledges that placing advertisements soliciting employees of the type then employed by the Company or its affiliates
in newspapers, Internet job sites and similar media generally accessible to the public shall not be deemed to be a breach of this
Section.

 

    	3 

     

    

 

(b)       No
Solicitation of Clients and Suppliers. I acknowledge the importance to the business carried on by the Company and its
affiliates of the client and supplier relationships developed by it and them and the unique opportunity that your employment or
engagement and your access to the Confidential Information offers to interfere with these relationships. Accordingly, you covenant
and agree that you shall not after the termination of your employment or engagement with the Company, directly or indirectly,
for a period of two (2) years, contact or solicit any person who you know to be a prospective, current or former client or supplier
of the Company or any affiliate for the purpose of selling to such client or buying from such supplier any Company Business products
or services.

 

12.        
Notification. I hereby authorize the Company to notify my actual or future employers of the terms of this Agreement
and my responsibilities hereunder.

 

13.        
Injunctive Relief. I understand that in the event of a breach or threatened breach of this Agreement by me the Company
may suffer irreparable harm and will therefore be entitled to injunctive relief to enforce this Agreement.

 

14.       
Governing Law; Jurisdiction. This Agreement will be governed by and construed in accordance with the laws of the State
of New Jersey, without giving effect to that body of laws pertaining to conflict of laws. I hereby submit to the jurisdiction
of and consent to suit in the courts, Federal and State located in the State of New York with respect to any matter or dispute
arising out of this Agreement.

 

15.       
Severability. If any provision of this Agreement is determined by any court or arbitrator of competent jurisdiction
to be invalid, illegal or unenforceable in any respect, such provision will be enforced to the maximum extent possible given the
intent of the parties hereto. If such clause or provision cannot be so enforced, such provision shall be stricken from this Agreement
and the remainder of this Agreement shall be enforced as if such invalid, illegal or unenforceable clause or provision had (to
the extent not enforceable) never been contained in this Agreement.

 

16.      
  Counterparts. This Agreement may be executed in any number of counterparts, each of which when so executed
and delivered will be deemed an original, and all of which together shall constitute one and the same agreement.

 

17.       
Entire Agreement. This Agreement and the documents referred to herein constitute the entire agreement and understanding
of the parties with respect to the subject matter of this Agreement, and supersede all prior understandings and agreements, whether
oral or written, between or among the parties hereto with respect to the specific subject matter hereof.

 

18.       
Amendment and Waivers. This Agreement may be amended only by a written agreement executed by each of the parties hereto.
No amendment of or waiver of, or modification of any obligation under this Agreement will be enforceable unless set forth in a
writing signed by the party against which enforcement is sought. Any amendment effected in accordance with this section will be
binding upon all parties hereto and each of their respective successors and assigns. No delay or failure to require performance
of any provision of this Agreement shall constitute a waiver of that provision as to that or any other instance. No waiver granted
under this Agreement as to any one provision herein shall constitute a subsequent waiver of such provision or of any other provision
herein, nor shall it constitute the waiver of any performance other than the actual performance specifically waived.

 

    	4 

     

    

 

19.        
Successors and Assigns; Assignment. Except as otherwise provided in this Agreement, this Agreement, and the rights
and obligations of the parties hereunder, will be binding upon and inure to the benefit of their respective successors, assigns,
heirs, executors, administrators and legal representatives. The Company may assign any of its rights and obligations under this
Agreement to any entity which is my employer. No other party to this Agreement may assign, whether voluntarily or by operation
of law, any of its rights and obligations under this Agreement, except with the prior written consent of the Company.

 

20.        
Further Assurances. The parties agree to execute such further documents and instruments and to take such further actions
as may be reasonably necessary to carry out the purposes and intent of this Agreement.

 

SIGNED
THIS 25th DAY OF OCTOBER 2017

 

/s/
Yu Zhou

Yu
Zhou

 

GENEXOSOME
TECHNOLOGIES INC.

 

By:
/s/David Jin

 

Name:
David Jin

 

Title:
Co-CEO

 

    	5

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00275-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00275-of-00352.parquet"}]]